Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas

Su-Min Ha¹, Shin Hwang¹, Jin Young Park², Young-Joo Lee¹, Ki-Hun Kim¹, Gi-Won Song¹, Dong-Hwan Jung¹, Yun-Suk Yu², Jinpyo Kim², Kyoung-Jin Lee², Eunyoung Tak², Yo-Han Park³, Sung-Gyu Lee¹

¹Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
²CBS Bioscience, Inc., Daejeon, Korea
³Department of Fusion Medicine, Asan Medical Center, Seoul, Korea
⁴Department of Surgery, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea

INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most common malignancies around the world, and thus one of the leading causes of cancer-related death [1]. In patients with small, solitary HCCs, various locoregional treatments are indicated, but hepatic resection (HR) is still considered the first-line therapy in patients with preserved hepatic function [2,3]. However, tumor recurrence frequently develops following curative HR for small solitary HCCs, and the risk of recurrence is greater after HR for multiple or large HCCs. There are various risk factors influencing the postresection prognosis.
of HCC, but with respect to small solitary HCCs specifically, only a few clinicopathological factors, such as microvascular invasion (MVI), are known to be of limited value [4-6]. Thus, it is clinically important to identify prognostic factors that are reliably applicable to HR for small solitary HCCs.

The OncoHepa test (CbsBioscience Inc., Daejeon, Korea), a multigene expression profile test, was developed to assess the risk of tumor recurrence and death in patients with HCC. After validation through a multicenter study [7], it was licensed as a new Health Technology by the Ministry of Health and Welfare in Korea in 2010. Another prognostic prediction model, the ADV score, in which the levels of expression of 2 tumor markers—α-FP and des-γ-carboxy prothrombin (DCP)—are multiplied by the tumor volume (TV), was also developed to quantify the biological aggressiveness of HCC and to predict postresection prognosis [3].

Although these 2 tests are applicable to HCCs of any size, in this study, we focused on validation of their predictive power in patients who underwent curative HR for naïve, solitary HCCs of ≤5 cm.

METHODS

Patient selection

Our institutional liver cancer surgery database was searched extensively to identify patients who underwent macroscopic curative resection for naïve solitary HCCs ≤5 cm between January 2010 and December 2011. After matching with the HCC patient list at the Bio-Resource Center at our institution, 35 patients were identified whose HCC tissues were stored in a fresh-frozen state at -80°C. These 35 patients were enrolled in this study, and their fresh-frozen HCC tissues were examined by OncoHepa test. Their medical records were retrospectively reviewed after approval by the Institutional Review Board of Asan Medical Center (IRB 2017-0575). Patients were followed until March 2017 through a review of institutional medical records and National Health Insurance Service records, resulting in a follow-up period of ≥7 years, or until patient death.

Preoperative evaluation, surgical procedures, and follow-up

The preoperative imaging evaluation for HCC included dynamic abdomen and pelvis CT, chest CT, and MRI. The hepatic functional reserve was assessed using the indocyanine green retention rate at 15 minutes and the evidence of portal hypertension on imaging and endoscopic studies. The extent of HR was determined by the proportion of the future liver remnant volume after consideration of tumor-free resection margins and the hepatic functional reserve. Perioperative evaluation, perioperative follow-up, and treatment for tumor recurrence were described previously [2,3,8-10].

OncoHepa test

The OncoHepa test was performed with the fresh-frozen HCC tissue samples stored at the Bio-Resource Center at our institution. This study assesses the signature of 4 genes (CDH1, ID2, MMP9, and TCF3) by quantitative real-time polymerase chain reaction (PCR) [7].

RNA extraction and cDNA synthesis

Total RNA was extracted from HCC tissues using the RNeasy mini kit (Qiagen, Hilden, Germany). Samples containing 4 μg of total RNA were incubated with 2 μL of 10 μM oligo d(T)₃ primer (Genotech, Daejeon, Korea) at 70°C for 7 minutes and cooled on ice for 5 minutes. After adding the enzyme mix to the annealed total RNA sample, the reaction was incubated for 90 minutes at 42°C prior to heat inactivation of the reverse transcriptase at 80°C for 10 minutes. The cDNA samples were brought up to a final volume of 400 μL with the addition of diethylpyrocarbonate-treated water.

Quantitative real-time PCR

Using Applied Biosystems Prism 7900HT instruments (Applied Biosystems, Foster City, CA, USA), the real-time PCR analysis was performed in a total volume of 10 μL with the following amplification steps: an initial activation step at 95°C for 10 minutes, followed by 45 cycles of denaturation at 95°C for 15 seconds and elongation at 60°C for 1 minute. The primer and probe sequences were designed using Primer Express 3.0 software (Applied Biosystems) (Table 1), and all probe sequences were labeled with FAM at the 5’ end and with TAMRA at the 3’ end. The mRNA levels of 4 target genes (CDH1, ID2, MMP9, and TCF3) were measured in triplicate and then normalized relative to a set of reference genes.

Table 1. Oligonucleotide sequences of polymerase chain reaction primers and probes

| Gene | Sequence |
|------|----------|
| CDH1 Forward: 5’-AAA TCT GAA AGC GCC TGA TAC TG-3’<br>Reverse: 5’-CGG AAC CGC TTC CTT CAT AG-3’<br>Probe: 5’-CCC CAC AGC CCC GCC TTA TGA-3’ |
| ID2 Forward: 5’-AAC GAC TGC TAC TCC AAG CTC AA-3’<br>Reverse: 5’-GGA TTT CCA TCT TGC TCA CCT T3’<br>Probe: 5’-TGC CCA GCA TCC CCC AGA ACA A-3’ |
| MMP9 Forward: 5’-GGG CTC CCG TCC TCG TGC TT-3’<br>Reverse: 5’-ACT CCT CCC TTT CCT CCA GAA C-3’<br>Probe: 5’-TGC CAT GTA AAT CCC CAC TGG GAC C-3’ |
| TCF3 Forward: 5’-GGG GCC TTC TTT GGG GCT TGC TT-3’<br>Reverse: 5’-AGA AAT CCA ATG CTC AGT CTA GGA-3’<br>Probe: 5’-AGT CCC GTG TCT CTC GCT ATT TCT GCT G-3’ |
genes beta-2-microglobulin, glyceraldehyde 3-phosphate dehydrogenase, hydroxymethylbilane synthase, hypoxanthine phosphoribosyltransferase 1, and succinate dehydrogenase complex flavoprotein subunit A, by subtracting the average of the expression of the 5 reference genes as an internal control. Details of these procedures were described previously [7,11,12].

**Calculation of risk score**

Risk score was derived by the summation of each gene expression level multiplied by its corresponding coefficient.

**Table 2. Comparison of the clinicopathological characteristics in the low-risk group and the high-risk group according to the OncoHepa test**

| Parameter                         | Low-risk group (n = 28) | High-risk group (n = 7) | P-value |
|-----------------------------------|-------------------------|-------------------------|---------|
| Age (yr)                          | 54.0 ± 6.3              | 54.4 ± 7.8              | 0.55    |
| Sex, male:female                  | 21:7                    | 6:1                     | >0.99   |
| HBs Ag (+)                        | 28 (100)                | 6 (85.7)                | 0.20    |
| HCV Ab (+)                        | 0 (0)                   | 1 (14.3)                | >0.99   |
| ICG-R15 (%)                       | 14.9 ± 4.9              | 16.3 ± 5.7              | 0.47    |
| Liver function test               |                         |                         |         |
| Albumin (g/dL)                    | 3.3 ± 0.7               | 3.3 ± 0.7               | 0.94    |
| Total bilirubin (mg/dL)           | 1.2 ± 0.4               | 1.2 ± 0.5               | 0.37    |
| Prothrombin time (INR)            | 1.2 ± 0.2               | 1.2 ± 0.2               | 0.71    |
| Platelet count (10^3/μL)          | 141 ± 34                | 157 ± 25                | 0.55    |
| α-FP (mg/mL)                      |                         |                         |         |
| Mean                              | 303.3 ± 885.2           | 160.2 ± 264.3           | 0.42    |
| Median                            | 19.1                    | 14.8                    |         |
| DCP (mAU/mL)                      |                         |                         |         |
| Mean                              | 729.3 ± 1612.9          | 162.4 ± 334.8           | 0.14    |
| Median                            | 50                      | 31                      |         |
| Liver cirrhosis                   |                         |                         | 0.31    |
| Type of hepatic resection         |                         |                         | >0.99   |
| Right hepatectomy                 | 2 (7.1)                 | 1 (14.3)                |         |
| Left hepatectomy                  | 1 (3.6)                 | 1 (14.3)                |         |
| Right anterior sectionectomy      | 8 (28.6)                | 2 (28.6)                |         |
| Right posterior sectionectomy     | 8 (28.6)                | 1 (14.3)                |         |
| Left lateral sectionectomy        | 1 (3.6)                 | 0 (0)                   |         |
| Left medial sectionectomy         | 1 (3.6)                 | 0 (0)                   |         |
| Partial hepatectomy               | 7 (25.0)                | 2 (28.6)                |         |
| Tumor size (cm)                   |                         |                         | 0.60    |
| Mean                              | 3.4 ± 1.0               | 3.3 ± 1.0               |         |
| Median                            | 3.0                     | 3.0                     |         |
| Tumor volume (mL)                 |                         |                         | 0.38    |
| Mean                              | 25.3 ± 20.0             | 23.6 ± 17.9             |         |
| Median                            | 14.1                    | 14.1                    |         |
| Microvascular invasion            |                         |                         | >0.99   |
| Edmondson-Steiner tumor differentiation (n) |           |                         |         |
| Worst, I–III–IV                   | 6:22                    | 3:4                     | 0.34    |
| Most, I–III–IV                    | 15:13                   | 4:3                     | >0.99   |
| ADV score (log_{10})              |                         |                         | 0.94    |
| Mean                              | 4.7 ± 1.6               | 4.3 ± 1.5               |         |
| Median                            | 4.5                     | 3.8                     |         |
| Tumor stage                       |                         |                         | >0.99   |
| 7th AJCC, T1:T2                   | 25:3                    | 1:6                     |         |
| 8th AJCC, T1a:T1b:T2              | 4:21:3                  | 1:6:0                   | >0.99   |
| BCLC, 0:A                         | 2:26                    | 1:6                     | 0.50    |

Values are presented as mean ± standard deviation or number (%). ICG-R15, indocyanine green retention rate at 15 minutes; DCP, des-γ-carboxy prothrombin; AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; ADV score, multiplication of α-FP, DCP, and tumor volume expressed in log_{10}. *Anatomical resection vs. partial hepatectomy.
Fig. 1. Postresection cumulative tumor recurrence (A) and overall patient survival (B).

Fig. 2. Postresection cumulative tumor recurrence (A, C, E) and overall patient survival (B, D, F) according to microvascular invasion (A, B), the OncoHepa test (CbsBioscience Inc., Daejeon, Korea) (C, D), and the ADV score (E, F).

Table 3. Multivariate analyses of the risk factors associated with tumor recurrence and patient survival

| Parameter                                      | Tumor recurrence | Patient survival |
|-----------------------------------------------|------------------|-----------------|
|                                               | HR   | 95% CI | P-value | HR   | 95% CI | P-value |
| OncoHepa test (high risk vs. low risk)        | 2.2  | 0.9–5.5 | 0.098   | 4.1  | 1.2–14.3 | 0.025 |
| ADV score (>4log vs. ≤4log)                    | 2.2  | 0.9–6.2 | 0.098   | 4.1  | 1.2–14.3 | 0.025 |

HR, hazard ratio; CI, confidence interval.
as follows: risk score = (-0.333 × CDH1) + (-0.400 × ID2) + (0.339 × MMP9) + (0.387 × TCF3), wherein CDH1, ID2, MMP9, and TCF3 refer to the log2-transformed and normalized results for each gene. The risk score was used to stratify the patients into high-risk (>0.303) or low-risk (<0.303) groups. High risk indicates poor patient survival [7].

ADV score integrated with tumor markers and TV

Multiplication of the α-FP (ng/mL), the DCP level (or protein-induced by vitamin K absence or antagonist-II; mAU/mL) and TV (mL) gives the ADV score, which is expressed on the logarithmic scale (log10) [3,10]. The ADV score was developed to quantify the biological aggressiveness of HCC and to predict postresection prognosis of HCC; its cutoff for post-resection prognosis of small HCC was set to 4log.

Statistical analysis

Continuous variables were analyzed by using the Student t-test or analysis of variance, depending on the distribution. Incidence variables were compared by the chi-square test or Fisher exact test. Survival curves were estimated by the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazards regression analysis was used to obtain the hazard ratio and 95% confidence interval. Statistical significance was set at P <0.05, and in certain analyses, P-values between 0.05 and 0.10 were considered to be marginally significant after consideration of the small sample number. IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA) was used for statistical analyses.

RESULTS

Clinicopathological features

The clinical and pathological features of the 35 study patients are summarized in Table 2. HBV infection was present in 34 patients (96.1%). No patient underwent any HCC treatment before HR. Preoperative liver function tests showed no difference between the OncoHepa low- and high-risk groups.

The types of HR were anatomical resection in 28 patients (80.0%) and nonanatomical partial hepatectomy in 7 patients (20.0%). The median tumor diameter was 3.0 cm (range, 1.7–5.0 cm), and the median TV was 14.1 mL (range, 2.6–65.4 mL). Pathological study revealed that MVI was present only in 3 patients (8.6%). No patient showed evidence of macrovascular invasion or satellite nodules. Liver cirrhosis was present in 29 patients (82.9%).

Tumor recurrence and patient survival

There was no perioperative mortality within 3 months. During the mean follow-up period of 61.1 ± 20.5 months (range, 7.6–86.2 months), tumor recurrence was identified in 20 patients (57.1%). Prognostic analysis indicated that the cumulative 1-, 3- and 5-year tumor recurrence rates were 28.6%, 48.6%, and 54.3%, respectively (Fig. 1A). All-cause death occurred in 12 patients (34.3%), all of whom died from HCC recurrence. The 1-, 3-, and 5-year overall patient survival rates were 100%, 82.9%, and 71.4%, respectively (Fig. 1B).

The site of the first tumor recurrence was the remnant liver in 18 patients, the lung in 1 patient, and the peritoneum in 1 patient. All patients with HCC recurrence received locoregional treatment including transcatheral chemoembolization (n = 16), radiofrequency ablation (n = 1), resection of the pulmonary metastasis (n = 1), and peritoneal seeding (n = 1).

Risk factor analysis for tumor recurrence and patient survival

Univariate analyses for tumor recurrence and patient survival were performed according to MVI, OncoHepa test results, and the ADV score.

The cumulative 5-year tumor recurrence rate was 56.2% in 32 MVI-negative patients and 33.3% in 3 MVI-positive patients (P = 0.55, Fig. 2A). The cumulative 5-year patient survival rate was 68.8% in 32 MVI-negative patients and 100% in 3 MVI-positive patients (P = 0.81, Fig. 2B).

The cumulative 5-year tumor recurrence rate was 50.0% in 28 OncoHepa low-risk patients and 71.4% in 7 OncoHepa high-risk patients (P = 0.097, Fig. 2C). The cumulative 5-year patient survival rate was 78.6% in 28 OncoHepa low-risk patients and 42.9% in 7 OncoHepa high-risk patients (P = 0.048, Fig. 2D).

The cumulative 5-year tumor recurrence rate was 41.2% in 17 ADV score ≤4log patients and 66.7% in 18 ADV score >4log patients (P = 0.098, Fig. 2E). The cumulative 5-year patient survival rate was 82.4% in 17 ADV score ≤4log patients and 61.1% in 18 ADV score >4log patients (P = 0.096, Fig. 2F).

Fig. 3. Proportions of the patients in the indicated groups according to the OncoHepa test (CbsBioscience Inc., Daejeon, Korea) and the ADV score. The left-sided group indicates the combined low-risk group and the sum of the three right-sided groups indicates the combined high-risk group.
Combination of the OncoHepa test and the ADV score

Because univariate analyses using OncoHepa findings or the ADV score with a 4log cutoff showed marginally statistically significant differences, we considered that these parameters might be independent prognostic factors and performed multivariate analyses for tumor recurrence and patient survival (Table 3). Thus, the OncoHepa findings and ADV score were

Table 4. Comparison of the clinicopathological characteristics in the combined low-risk group and the combined high-risk group according to the OncoHepa test finding and ADV score with 4log cutoff

| Parameter                               | Combined low-risk group (n = 13) | Combined high-risk group (n = 22) | P-value |
|-----------------------------------------|----------------------------------|----------------------------------|---------|
| Age (yr)                                | 53.9 ± 5.8                       | 54.2 ± 7.0                       | 0.42    |
| Sex, male:female                        | 11:2                             | 16:6                             | 0.68    |
| HBs Ag (+)                              | 13 (100)                         | 21 (95.5)                        | >0.99   |
| HCV Ab (+)                              | 0 (0)                            | 1 (4.5)                          | >0.99   |
| ICG-R15 (%)                             | 13.9 ± 4.5                       | 16.0 ± 5.3                       | 0.45    |
| Liver function test                     |                                  |                                  |         |
| Albumin (g/dL)                          | 3.5 ± 0.6                        | 3.2 ± 0.7                        | 0.73    |
| Total bilirubin (mg/dL)                 | 1.1 ± 0.4                        | 1.3 ± 0.5                        | 0.28    |
| Prothrombin time (INR)                  | 1.1 ± 0.1                        | 1.2 ± 0.2                        | 0.098   |
| Platelet count (10^3/μL)                | 147 ± 35                         | 142 ± 32                         | 0.58    |
| α-FP (ng/mL)                            |                                  |                                  |         |
| Mean                                    | 7.5 ± 8.6                        | 432.6 ± 981.1                    | 0.028   |
| Median                                  | 4.1                              | 41.6                             |         |
| DCP (mAU/mL)                            |                                  |                                  |         |
| Mean                                    | 52.2 ± 61.2                      | 949.1 ± 1,774.6                  | 0.002   |
| Median                                  | 33                               | 60                               |         |
| Liver cirrhosis (n)                     | 11 (84.6)                        | 18 (81.8)                        | >0.99   |
| Type of hepatic resection (n)           |                                  |                                  | 0.72*   |
| Right hepatectomy                       | 1 (7.7)                          | 2 (9.1)                          |         |
| Left hepatectomy                        | 0 (0)                            | 2 (9.1)                          |         |
| Right anterior sectionectomy            | 4 (30.8)                         | 6 (27.3)                         |         |
| Right posterior sectionectomy           | 3 (23.1)                         | 6 (27.3)                         |         |
| Left lateral sectionectomy              | 0 (0)                            | 1 (4.5)                          |         |
| Left medial sectionectomy               | 1 (7.7%)                         | 0 (0)                            |         |
| Partial hepatectomy                     | 4 (30.8)                         | 5 (22.7)                         |         |
| Tumor size (cm)                         |                                  |                                  |         |
| Mean                                    | 3.0 ± 1.0                        | 3.6 ± 1.0                        | 0.097   |
| Median                                  | 2.7                              | 3.5                              |         |
| Tumor volume (mL)                       |                                  |                                  |         |
| Mean                                    | 18.3 ± 16.8                      | 28.9 ± 20.1                      | 0.22    |
| Median                                  | 10.3                             | 22.4                             |         |
| Microvascular invasion                  |                                  |                                  | 0.55    |
| Worst, I-II:III-IV                      | 4:9                              | 5:17                             | 0.70    |
| Most, I-II:III-IV                       | 9:4                              | 10:12                            | 0.29    |
| ADV score (log_{10})                    |                                  |                                  |         |
| Mean                                    | 2.3 ± 0.5                        | 5.4 ± 1.4                        | 0.010   |
| Median                                  | 3.3                              | 5.5                              |         |
| Tumor stage                              |                                  |                                  |         |
| 7th AJCC, T1:T2                         | 11:2                             | 21:1                             | 0.54    |
| 8th AJCC, T1a:T1b:T2                    | 3:8:2                            | 2:19:1                           | 0.54    |
| BCLC, 0:A                               | 2:11                             | 1:21                             | 0.54    |

Values are presented as mean ± standard deviation or number (%).

ICG-R15, indocyanine green retention rate at 15 minutes DCP, des-γ-carboxy prothrombin AJCC, American Joint Committee on Cancer BCLC, Barcelona Clinic Liver Cancer ADV score, multiplication of α-FP, DCP, and tumor volume expressed in log_{10}.

*Anatomical resection vs. partial hepatectomy.
combined, and patients were divided into 2 groups: the combined high-risk group (OncoHepa high-risk or ADV score >4log) and the combined low-risk group (OncoHepa low-risk and ADV score ≤4log) (Fig. 3). The clinical and pathological features of study patients belonged to the combined low- and high-risk groups are summarized in Table 4, in which significant difference was present in \(\alpha\)-FP, DCP, and ADV score.

The cumulative 5-year tumor recurrence rate was 30.8% in 13 combined low-risk patients and 68.2% in 22 combined high-risk patients (P = 0.046, Fig. 4A). The cumulative 5-year patient survival rate was 92.3% in 13 combined low-risk patients and 59.1% in 22 combined high-risk patients (P = 0.048, Fig. 4B).

**DISCUSSION**

HCC is a unique disease with highly heterogeneous clinicopathological features, and is thus difficult to treat effectively and to predict prognosis reliably. Tumor size is one of the most important prognostic factors following HR in HCC. We previously demonstrated that the resection prognosis gradually worsens according to an incremental increase in HCC size, from 1 cm to 10 cm, regardless of the MVI status [2]. In solitary HCCs, the incidence of MVI was 31% in HCCs ≤5 cm, 41% in HCCs of 5.1–6.5 cm, and 58% in HCCs >6.5 cm [13]. We also showed that the incidence of MVI progressively increases with size, from 4.1% in HCCs <2 cm to 13.1% in HCCs of 2.1–4.0 cm, 20.6% in HCCs of 4.1–5.9 cm, 31.5% in HCCs of 6.1–7.9 cm, and 30.7% in HCCs of 8.1–9.9 cm [2]. In the present study, MVI was present in only 8.6% (3 of 35) of patients with solitary HCCs ≤5 cm probably due to intentional selection of small-sized tumors. Because of its low incidence and lower prognostic impact in small-sized HCCs, MVI often cannot be used as an independent prognostic factor in patients with small HCCs [4,10]. Therefore it is necessary to identify other prognostic factors applicable to small HCCs.

The OncoHepa test is a multi-gene expression profile test for risk stratification that uses a cutoff value obtained from a high-volume multicenter study [7]. The four genes used in the OncoHepa test are associated with epithelial-mesenchymal transition (EMT), which plays a critical role in epithelial cancer progression [14]. During development of the OncoHepa test, 12 genes related to EMT process were assessed and then a prognostic 4-gene signature was constructed through training and validation studies [7].

The 4 genes used in the OncoHepa test are associated with tumor invasion and metastasis. E-cadherin (CDH1) is a prominent epithelial marker, as the main component of adherent junctions [14] Lower expression of E-cadherin was reported to be associated with poor prognosis [15]. ID2 belongs to the helix-loop-helix family of proteins and represses EMT induced by transforming growth factor-\(\beta\) in epithelial cells [16]. Lower ID2 expression was correlated with higher recurrence in HCC patients [17], and with dedifferentiation of HCC [18]. Matrix metalloproteinases (MMPs) are reported to be upregulated in cells that have undergone EMT as well as in cells capable of inducing EMT [19,20]. Overexpression of MMP9 was linked to the growth of small HCCs [21,22] and correlated with poor prognosis [21-24]. In addition, the expression of transcription factor 3 (TCF3) is reported to be associated with prognosis [7]. TCF3 and Twist are potent repressors of E-cadherin expression [25,26].

The present study suggests that the OncoHepa test is clinically useful for predicting risk of tumor recurrence and patient survival after HR of solitary HCCs ≤5 cm. Its predictive power was greater than that of other established prognostic factors, including MVI, although it showed marginal statistical significance due to the small sample number. In fact, the concept of gene expression signatures for predicting cancer
prognosis is no longer unique. Multiple gene expression signatures have been developed for predicting the prognosis of breast cancers, and they are already included as essential parts of the treatment guidelines for breast cancers [27,28].

Only a very small amount of HCC tissue is necessary for the OncoHepa test: thus, a very thin thread of HCC tissue obtained from a percutaneous liver biopsy can be a suitable specimen. The present study and previous validation studies of the OncoHepa test have used fresh-frozen HCC tissues, which were obtained during HR and preserved at -80°C. This test uses RNA extracted from fresh-frozen HCC tissue, thus HCC tissues preserved in paraffin-embedded blocks may not be suitable probably due to the difficulty of reliable RNA extraction [29,30]. Thus, it is practical to perform this test at the time HCC specimens are prepared for pathological examination after HR.

The ADV score is another prognostic parameter reflecting the tumor biology. Its suitability for use in clinical practice was demonstrated in our previous studies [3,10]. The results of the present study also suggest that the ADV score with a cutoff at 4log is a useful predictor of the risk of tumor recurrence and patient survival after HR of solitary HCCs ≤5 cm. Its predictive power was comparable to that of the OncoHepa test, although it also showed a marginal statistical significance due to the small sample number. Multivariate analyses revealed that these 2 parameters can be independent prognostic factors. Therefore, we combined the two to create a new prognostic prediction model. If any of 2 parameters is high risk, the patient is considered to have a combined high risk. Combined high-risk patients showed significantly inferior outcomes compared to combined low-risk patients. Thus, we think that this combined risk model will be useful to predict patients with a truly low risk of tumor recurrence and patient survival. If the 2 test parameters are available, the combined prognostic prediction power will be greatly enhanced. If only one parameter is available, its prognostic predictive power is still strong enough to be clinically valid.

The present study had some limitations of note. This was a small-volume, single-center study in a HBV-endemic country. Hence, it will be necessary to validate our results in multiple centers and in other geographic regions with different background liver diseases. Another limitation of the present study was that we selected only patients with solitary, small HCCs to avoid bias from inevitable confounding variables.

In conclusion, our results support previous reports that both the OncoHepa test and the ADV score have considerably strong prognostic power in patients who underwent HR of solitary HCCs ≤5 cm. Therefore, the individual and combined findings of the OncoHepa test and the ADV score are helpful to guide postresection surveillance for tumor recurrence and to predict patient survival.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGEMENTS

This study was supported by the Basic Science Research Program of the National Research Foundation of Korea (NRF), which is funded by the Ministry of Science, Information and Communications Technology, and Future Planning (Grant No 2015R1A2A2A04007141).

REFERENCES

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55.
2. Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, Ha TY, et al. The impact of tumor size on long-term survival outcomes after resection of solitary hepatocellular carcinoma: single-institution experience with 2558 patients. J Gastrointest Surg 2015;19:1281-90.
3. Hwang S, Song GW, Lee YJ, Kim KH, Ahn CS, Moon DB, et al. Multiplication of tumor volume by two tumor markers is a post-resection prognostic predictor for solitary hepatocellular carcinoma. J Gastrointest Surg 2016;20:1807-20.
4. Shindoh J, Andreou A, Aloia TA, Zimmitti G, Lauwers GY, Laurent A, et al. Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors. Ann Surg Oncol 2013;20:1223-9.
5. Shindoh J, Hasegawa K, Inoue Y, Ishizawa T, Nagata R, Aoki T, et al. Risk factors of post-operative recurrence and adequate surgical approach to improve long-term outcomes of hepatocellular carcinoma. HPB (Oxford) 2013;15:31-9.
6. Roayaie S, Obeidat K, Sposito C, Mariani L, Bhouri S, Pellegrinelli A, et al. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology 2013;57:1426-35.
7. Kim J, Hong SJ, Park JY, Park JH, Yu YS, Park SY, et al. Epithelial-mesenchymal transition gene signature to predict clinical outcome of hepatocellular carcinoma. Cancer Sci 2010;101:1521-8.
8. Hwang S, Ha TY, Song GW, Jung DH, Ahn CS, Moon DB, et al. Quantified Risk assessment for major hepatectomy via the indocyanine green clearance rate and liver volumetry combined with standard liver volume. J Gastrointest Surg 2015;19:1305-14.
9. Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75.
10. Jung DH, Hwang S, Lee YJ, Kim KH, Song GW, Ahn CS, et al. Small hepatocellular carcinoma with low tumor marker expression benefits more from anatomical resection than tumors with aggressive biology. Ann Surg 2017 Aug 23 [Epub]. https://doi.org/10.1097/SLA.0000000000002486.
11. Kim J, Hong SJ, Lim EK, Yu YS, Kim SW, Roh JH, et al. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res 2009;28:20.
12. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
13. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005;11:1086-92.
14. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009;1796:75-90.
15. Yang MH, Chen CL, Chau GY, Chiou SH, Su CW, Chou TY, et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology 2009;50:1464-74.
16. Kowanetz M, Valcourt U, Bergstrom R, Heldin CH, Moustakas A. Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. Mol Cell Biol 2004;24:4241-54.
17. Tsunedomi R, Iizuka N, Tamesa T, Sakamoto K, Hamaguchi T, Somura H, et al. Decreased ID2 promotes metastatic potentials of hepatocellular carcinoma by altering secretion of vascular endothelial growth factor. Clin Cancer Res 2008;14:1025-31.
18. Damdinsuren B, Nagano H, Kondo M, Yamamoto H, Hiraoka N, Yamamoto T, et al. Expression of Id proteins in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Int J Oncol 2005;39:1082-8.
19. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006;6:764-75.
20. Przybloy JA, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition: tumor progression at Snail’s pace. Int J Biochem Cell Biol 2007;39:1082-8.
21. Sakamoto Y, Mafune K, Mori M, Shiraiishi T, Imamura H, Mori M, et al. Overexpression of MMP-9 correlates with growth of small hepatocellular carcinoma. Int J Oncol 2000;17:237-43.
22. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002;8:385-92.
23. Hayasaki A, Suzuki N, Fujimoto N, Iwama S, Fukuyama E, Kanda Y, et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/ gelatinase B) in hepatocellular carcinoma. Hepatology 1996;24:1058-62.
24. Chen ZB, Shen SQ, Ding YM, Wang WX, Tao JP, Lian LJ, et al. The angiogenic and prognostic implications of VEGF, Ang-1, Ang-2, and MMP-9 for hepatocellular carcinoma with background of hepatitis B virus. Med Oncol 2009;26:365-71.
25. Perez-Moreno MA, Locascio A, Rodrigo I, Dhondt G, Portillo F, Nieto MA, et al. A new role for E12/E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions. J Biol Chem 2001;276:27424-31.
26. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-39.
27. Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol 2017;35:2838-47.
28. Delahaye LJ, Drukker CA, Dreeszen C, Witteveen A, Chan B, Snel M, et al. A breast cancer gene signature for indolent disease. Breast Cancer Res Treat 2017;164:461-6.
29. Vaira V, Roncalli M, Carnaghi C, Favero sani A, Maggioni M, Augello C, et al. MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. Liver Int 2015;35:1077-86.
30. Chen R, Guan Q, Cheng J, He J, Liu H, Cai H, et al. Robust transcriptional tumor signatures applicable to both formalin-fixed paraffin-embedded and fresh-frozen samples. Oncotarget 2017;8:6652-62.